Tempus AI, Inc. Class A Common Stock (TEM)
Tempus AI, Inc. Class A (TEM) is a technology company focused on developing artificial intelligence-driven solutions. It specializes in leveraging AI to improve efficiency and decision-making in various industries, including finance, healthcare, and enterprise services. The company aims to deliver innovative software and data analytics tools to enhance business operations and insights.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 28, 2006 | $0.26 | 2006-07-18 | 2006-07-20 |
| July 28, 2006 | $0.44 | 2006-07-18 | 2006-07-20 |
| June 22, 2005 | $0.23 | 2005-06-10 | 2005-06-14 |
| June 28, 2004 | $0.22 | 2004-06-21 | 2004-06-23 |
| June 26, 2003 | $0.20 | 2003-06-16 | 2003-06-18 |
Dividends Summary
- Tempus AI, Inc. Class A Common Stock has issued 5 dividend payments over the past 3 years
- The most recent dividend was paid 7026 days ago, on July 28, 2006
- The highest dividend payed out to investors during this period was $0.44 per share
- The average dividend paid during this period was $0.27 per share.
Company News
Tempus AI, an artificial intelligence specialist in drug discovery, saw its share price increase by 5% following an analyst update from Cannacord Genuity's Kyle Mikson, who remains bullish on the company's potential in medical technology and AI-driven pharmaceutical innovation.
Tempus AI's stock has surged 155% since its IPO, reaching $100 per share. Recent FDA clearances for medical imaging and cancer cell analysis devices, along with potential government support for pediatric cancer research, have driven its growth. However, analysts suggest the stock might be overvalued and due for a correction.
Several large-cap stocks experienced significant declines last week, with companies like Freeport-McMoRan, NuScale Power, and Oklo facing notable stock price drops due to various company-specific and market factors.
Law firm investigating potential claims against Tempus AI for alleged breaches of fiduciary duties, including inflated contract values, questionable business practices, and misleading financial reporting, following a Spruce Point Capital Management report.